The central message of the review is that Tfh cells are not a monolithic population. Instead, they display profound heterogeneity along two major axes: spatial distribution and phenotypic characteristics. Spatially, researchers now distinguish germinal center-resident Tfh cells, follicular mantle Tfh cells, circulating Tfh cells found in the bloodstream, and peripheral Tfh cells that populate inflamed tissues and tertiary lymphoid structures. Phenotypically, Tfh cells can be further subdivided into Tfh1, Tfh2, and Tfh17 subsets, each defined by distinct cytokine profiles and transcription factor dependencies. This layered diversity allows the immune system to tailor antibody responses to vastly different challenges, from acute viral infections to parasitic worms, but it also creates multiple points at which regulation can fail and pathology can emerge.

At the heart of Tfh cell differentiation lies a transcriptional tug-of-war between two master regulators: B-cell lymphoma 6, or Bcl-6, and cellular musculoaponeurotic fibrosarcoma oncogene homolog, better known as c-Maf. Bcl-6 is the lineage-defining factor that drives nascent CD4 T cells toward the follicular helper fate, enabling them to upregulate the chemokine receptor CXCR5, which guides their migration into B cell follicles, and to suppress alternative differentiation programs. Bcl-6 and its antagonist Blimp-1 form a reciprocal regulatory circuit: high Bcl-6 and low Blimp-1 favor Tfh commitment, whereas the opposite pattern pushes cells toward other effector fates. c-Maf, induced downstream of the costimulatory receptor ICOS, cooperates with Bcl-6 to promote expression of interleukin-21, the signature cytokine through which Tfh cells deliver help to B cells. Together, these factors orchestrate a gene expression program that is both robust and exquisitely sensitive to environmental cues.

That sensitivity is embodied by the cytokine milieu encountered during T cell priming. Interleukin-6, signaling through STAT1 and STAT3, promotes early Bcl-6 induction and Tfh differentiation, while interleukin-12 and type I interferons steer cells toward Tfh1-like phenotypes characterized by the transcription factor T-bet. Conversely, interleukin-2 acts as a brake: high IL-2 signaling through the mTORC1 pathway antagonizes Tfh differentiation, which is why IL-6-mediated suppression of IL-2 responsiveness is required for germinal center Tfh cells to emerge. Interleukin-4 and the transcription factors GATA3, Batf, and STAT6 define the Tfh2 compartment, whereas transforming growth factor-beta, acting through c-Maf and STAT3-STAT4 cooperation, can promote human Tfh differentiation and specify Tfh versus Th17 fates. Additional players such as Ascl2, Tox2, and the chromatin organizer SATB1 fine-tune chromatin accessibility and gene expression, while the kinase mTORC1 and extracellular matrix protein 1 further modulate the process.

The spatial dimension of Tfh biology has emerged as a particularly active research frontier. Landmark studies using intravital microscopy revealed that germinal center Tfh cells are highly motile, dynamically interacting with B cells in a competitive process that shapes antibody affinity maturation. Development of both germinal center B cells and Tfh cells initiates in the interfollicular zone, where antigen-presenting dendritic cells first license naive T cells before they migrate into follicles. Within germinal centers themselves, progressively differentiated Tfh subsets have been described, and recent work has identified physiologically distinct CXCR5-high, PD-1-high resident populations. Long-lived memory Tfh cells, which persist after infection or vaccination and retain remarkable plasticity, sustain humoral immunity for years, and memory-like Tfh subsets have been identified as precursors of effector Tfh cells during recall responses. Circulating CXCR5-positive CD4 T cells in human blood mirror these lymphoid tissue counterparts and contain subsets that differentially support antibody secretion, providing a convenient window into systemic humoral immunity.

The clinical significance of this heterogeneity becomes stark when Tfh subsets go awry. In viral infections, Tfh1 cells dominated by T-bet and STAT4 are critical for generating neutralizing antibodies against influenza, HIV, and SARS-CoV-2, and circulating Tfh responses in recovered COVID-19 patients have been correlated with durable antibody titers. Yet in autoimmune diseases, the very same differentiation programs can become pathological. In systemic lupus erythematosus, aberrant expansion of multiple Tfh subsets, including IL-17-producing and IL-4-producing populations, drives autoantibody production and nephritis, while T peripheral helper cells, a closely related CXCR5-negative population sharing the transcription factor c-Maf, promote B cell activation through MAF and IL-21. In rheumatoid arthritis, pathologically expanded peripheral T helper cells drive B cell responses in inflamed synovium, and STAT3 hyperactivation associates with disease activity. IgG4-related disease has been linked to CCR4-positive Tfh2 cells producing interleukin-4, and food allergy involves Tfh-derived programs that promote anaphylactic IgE, including a distinct Tfh13 subset stabilized by JunB.

Cancer adds yet another layer of complexity, because Tfh cells can play contradictory roles depending on context. Within tertiary lymphoid structures, the ectopic lymphoid aggregates that form inside tumors, Tfh cells collaborate with B cells to generate anti-tumor antibody-producing plasma cells, and neoantigen-driven collaboration between B cells and CD4 Tfh cells promotes cytotoxic CD8 T cell responses. Th1-oriented Tfh cells infiltrating breast cancer correlate with effective adaptive immunity, and microbiota-specific Tfh cells drive tertiary lymphoid structures and anti-tumor immunity in colorectal cancer. However, pro-tumor Tfh2 cells in pancreatic cancer induce detrimental IgG4 production, elevated IgG4 in melanoma patients is associated with disease progression, and regulatory T cells within tumor-associated tertiary lymphoid structures can suppress anti-tumor responses. VISTA-positive follicular regulatory T cells have been implicated in immune escape in ovarian cancer, making the Tfh-Tfr axis a potential target for combination immunotherapy.

Counterbalancing the helper activity of Tfh cells is a dedicated regulatory population: the T follicular regulatory cell, or Tfr cell. These Foxp3-positive and Bcl-6-positive cells suppress germinal center reactions, restrain cytokine production by Tfh cells, and optimize the quality of IgG responses. Tfr cells can be antigen-specific, derive from naive T cells, and even share clonal relationships with Tfh cells, with human Tfh clones shown to seed the germinal center-resident regulatory pool. Their stability and progressive differentiation are controlled by Tfh programs themselves. Mechanistically, Tfr cells deploy CTLA-4, PD-1, interleukin-10, and the neurotrophic factor neuritin to modulate B cell and T cell function, while the IL-2-mTORC1 axis and the transcription factors Bach2 and NFAT2 govern their development. Restoring the Tfr-to-Tfh balance has shown therapeutic promise in lupus nephritis models and in low-dose IL-2 trials for active SLE, and Tfr cells have been shown to restrain kidney allograft rejection by suppressing alloreactive B cells.

The translational implications of this work are already visible. The CD40 ligand antagonist dazodalibep has shown efficacy in a phase 2 trial for Sjogren’s disease, small molecules such as niclosamide and artesunate suppress Tfh expansion through STAT3 and JAK2-STAT3 pathways in lupus models, and OX40L-JAG1 cotreatment has restored follicular regulatory-helper balance in mice. As the Beijing Normal University team argues, integrating the multiple Tfh subsets into a unified systematic framework provides a new perspective for understanding humoral immune regulation and for developing targeted therapies that selectively boost protective antibody responses during infection and vaccination while dampening the pathological helper activity that fuels autoimmunity, allergy, and certain cancers. In an era when mRNA vaccines, checkpoint inhibitors, and CAR-T therapies all depend on or interact with the humoral arm of immunity, deciphering the rules that govern Tfh subset differentiation may prove to be one of immunology’s most consequential endeavors.

Subject of Research: Regulation of follicular helper T cell subset differentiation in humoral immunity, infection, autoimmunity, and cancer

Article Title: Regulation of follicular helper T cell subset differentiation in health and disease

Article References: Xin, Q., Zhao, L., Zhang, J., Liu, X., & Liu, G. (2026). Regulation of follicular helper T cell subset differentiation in health and disease. Journal of Molecular Medicine, 104(1), Article 115. https://doi.org/10.1007/s00109-026-02721-6

Image Credits: AI Generated

DOI: 10.1007/s00109-026-02721-6

Keywords: T follicular helper cells, germinal centers, Bcl-6, c-Maf, B cell help, antibody responses, autoimmunity, systemic lupus erythematosus, T follicular regulatory cells, tertiary lymphoid structures, cancer immunology, viral infection

The research team set out to address a persistent gap in reproductive virology. Viral infections in the female reproductive tract are well known to pose risks to fertility, and previous studies in mice have shown that viral infection of the ovaries can compromise pregnancy. Yet the specific impact of viruses on ovulated oocytes—the mature eggs that have just been released from the ovary—and the role played by the surrounding cumulus cells remained poorly understood. Cumulus cells form a layered, cloud-like structure called the cumulus oophorus around the oocyte, and together the egg and its companion cells are known as the cumulus–oocyte complex, or COC. This intimate relationship is metabolically essential: the oocyte depends on cumulus cells for nutrients, signaling molecules, and developmental cues throughout its maturation. What Sasaki and Kawahara wanted to know was whether this dependency could become a liability during a viral attack.

To model the situation, the researchers used vesicular stomatitis virus, or VSV, a bullet-shaped RNA virus that is a standard laboratory tool for studying antiviral immunity. VSV enters cells through clathrin-dependent endocytosis and replicates rapidly in the cytoplasm, making it a reliable trigger of the innate immune pathways that cells use to detect RNA viruses. The team exposed mouse cumulus–oocyte complexes to the virus and then assessed how the cells responded at the level of gene expression, using quantitative real-time PCR to measure antiviral transcripts. In parallel, they tracked developmental outcomes by fertilizing the exposed oocytes in vitro and counting how many progressed through cleavage divisions and on to the blastocyst stage, the last step before implantation.

The gene expression analysis revealed a striking asymmetry between the two cell types in the complex. Ovulated oocytes did express retinoic acid-inducible gene-I, known as RIG-I, which is the cytosolic receptor that detects RNA viruses inside infected cells. But the oocytes lacked expression of two other key sensors of the RIG-I family: melanoma differentiation-associated gene 5, or MDA5, and laboratory of genetics and physiology 2, or LGP2. These helicase genes were present in the cumulus cells. The finding matters because the RIG-I family of DExD/H-box helicases forms the front line of intracellular RNA virus detection, with RIG-I and MDA5 recognizing different classes of viral RNA and LGP2 acting as a regulatory partner that fine-tunes their activity. The differential expression suggests that the oocyte’s antiviral surveillance toolkit is incomplete, and that its defenses may rely heavily on the completeness of the cumulus cells’ immune machinery.

When intact cumulus–oocyte complexes were exposed to VSV, the consequences for development were clear. The virus significantly impaired preimplantation development, reducing both the rate at which fertilized eggs underwent cleavage and the rate at which embryos formed blastocysts. Yet when the researchers looked for evidence of actual viral infection inside the oocytes and early embryos, they found none. The authors attribute this protection to the zona pellucida, the glycoprotein shell that surrounds the oocyte and early embryo and acts as a physical barrier. This result reframes the problem: the damage to development occurs without the virus ever setting foot inside the cell it ultimately harms.

Several follow-up experiments cemented the indirect mechanism. First, when the researchers stripped the cumulus cells away and exposed denuded oocytes directly to VSV, the oocytes neither induced antiviral gene expression nor showed developmental defects. On their own, the eggs simply did not respond to the virus. Second, and most tellingly, when uninfected oocytes were co-cultured with VSV-infected cumulus cells, their development was impaired—demonstrating that the mere presence of infected neighbors, with no virus reaching the oocyte, was sufficient to cause the damage. The virus, in effect, converted the egg’s own nurse cells into a source of developmental toxicity.

The molecular signature of the infected cumulus cells explained why. The infected cells exhibited a robust antiviral response, with significant upregulation of RIG-I itself, interferon-beta, interleukin-6, and tumor necrosis factor-alpha. Interferon-beta is the classic first-responder signal of the antiviral state, while interleukin-6 and tumor necrosis factor-alpha are inflammatory cytokines that can act on neighboring cells. Crucially, the researchers found that oocytes and zygotes express the receptor subunits for interleukin-6, encoded by the genes Il6ra and Gp130. This means the egg is structurally equipped to receive and respond to IL-6 signals arriving from its surroundings. The interleukin-6 pathway is already known to play roles in preimplantation embryos, where the IL-6 family cytokine leukemia inhibitory factor is essential for implantation, and the IL-6/STAT3 axis has been linked to anti-apoptotic signaling in mouse embryos. The new data identify IL-6 as a candidate mediator of the developmental impairment caused by infected cumulus cells.

The study’s authors frame the findings as revealing both the protective and the vulnerable nature of the cumulus–oocyte complex during viral challenge. The cumulus cells act as a shield: their complete antiviral sensor repertoire allows them to detect and respond to the virus, and the physical barrier of the zona pellucida keeps the virus out of the oocyte. But the same activation that defends the complex also floods the perivitelline environment with inflammatory cytokines, and the oocyte, which lacks its own full complement of viral sensors, appears susceptible to the paracrine consequences. The work thus provides a mechanistic account of how the maternal inflammatory microenvironment can influence early embryonic success, even in the absence of direct infection of the embryo itself.

The implications extend to a broader literature on viral infection and fertility. Hepatitis E virus has been shown to replicate in the ovary and promote oocyte apoptosis in rabbits, and Zika virus has been shown to cause acute infection and inflammation in the mouse ovary, with sexual transmission routes documented in mouse models. Herpes simplex virus type 2 sheds asymptomatically in the human female genital tract, and viral infection of the ovaries has been shown to compromise pregnancy while also revealing innate immune mechanisms that protect fertility. The new study adds a distinct mechanism to this list: not direct ovarian infection, and not viral tropism for the gamete, but the transformation of the egg’s own supporting cells into cytokine factories that compromise its developmental competence. This pathway could be relevant to unexplained fertility deficits associated with systemic or reproductive tract viral illness.

For the assisted reproduction field, the results suggest that the health of cumulus cells is not merely a marker of oocyte quality but an active determinant of embryo outcomes under immune challenge. The work was supported by JSPS KAKENHI grants 24K09199, awarded to Sasaki, and 24K01902, awarded to Kawahara, and all animal experiments were approved by the Regulatory Committee for the Care and Use of Animals of Hokkaido University. The authors note that the datasets supporting the developmental rate findings are available in the supplementary materials, with other data available from the corresponding author on reasonable request. Future work, the study implies, will need to test whether blocking interleukin-6 signaling during viral illness can rescue the developmental potential of exposed oocytes, and whether the same paracrine mechanism operates in other species, including humans—questions that could shape how fertility preservation is approached in patients confronting acute viral infections of the reproductive tract.

Subject of Research: Antiviral responses of mouse cumulus–oocyte complexes and indirect viral impairment of oocyte developmental competence via cumulus cell inflammatory signaling.

Article Title: Viral Infection of Cumulus Cells Impairs the Developmental Competence of Ovulated Mouse Oocytes

Article References: Sasaki, K., & Kawahara, M. (2026). Viral Infection of Cumulus Cells Impairs the Developmental Competence of Ovulated Mouse Oocytes. Biochemical Genetics. https://doi.org/10.1007/s10528-026-11449-4

Image Credits: AI Generated

DOI: 10.1007/s10528-026-11449-4

Keywords: oocyte, cumulus cells, vesicular stomatitis virus, antiviral response, RIG-I, interleukin-6, zona pellucida, fertility, preimplantation embryo, paracrine signaling, viral infection, reproductive immunology

Herpetic whitlow results when herpes simplex virus, most commonly herpes simplex virus type 1, inoculates the skin of a digit through a break in the cutaneous barrier. The virus travels to sensory nerve endings, establishes infection in the distal phalanx, and produces one or more intensely painful vesicles that may coalesce into a larger blister resembling a bacterial felon or paronychia. The infection classically affects the thumb and index finger, though any digit may be involved. In children, autoinoculation from thumb-sucking or finger-sucking during oral herpetic infections is the dominant route of acquisition, while in adults the disease has historically been an occupational hazard among dentists, dental hygienists, and other health care workers exposed to oral secretions before the widespread adoption of gloves.

The historical record captured in the review begins with early observations that established whitlow as a nosocomial threat. Among the foundational works cited is a 1959 Lancet study by Stern and colleagues describing herpetic whitlow as a form of cross-infection in hospitals, a report that helped define the condition’s public health significance at a time when its viral etiology was still being separated from pyogenic infections of the hand. By the end of the twentieth century, larger clinical series such as the 1990 analysis by Gill and colleagues of herpes simplex virus infection of the hand, published in the Journal of the American Academy of Dermatology, had clarified the spectrum of disease in adults and children alike, documenting incubation periods, recurrence patterns, and the substantial morbidity that recurrent infection imposes on patients.

The technical groundwork for the present synthesis rests on several strands of evidence. Case reports of pediatric whitlow, exemplified by the 2001 European Journal of Pediatrics report by Szinnai and colleagues describing multiple herpetic whitlow lesions in a four-year-old girl, illustrate how extensive the lesions can become in young children and how easily the presentation can be mistaken for more common blistering disorders. Occupational case series, including the 2012 report by Browning and McCarthy in the Journal of Esthetic and Restorative Dentistry documenting herpes simplex virus as an occupational hazard among dental practitioners, reinforce the role of exposure routes in shaping who develops the disease. On the therapeutic side, the pharmacological understanding of nucleoside analogs such as acyclovir and its relatives has matured considerably, as summarized in the 2022 PharmGKB review by Maillard and colleagues of the acyclovir and ganciclovir metabolic pathway, which maps how these prodrugs are converted by viral and cellular thymidine kinases into active triphosphate forms that selectively inhibit viral DNA polymerase.

By pooling published case material, the Weill Cornell-led team sought to define the epidemiological and clinical profile of herpetic whitlow with more precision than any single case report could provide. The review’s design reflects a growing appreciation in dermatology that rare or underrecognized conditions accumulate meaningful evidence only when scattered reports are aggregated and analyzed together. The researchers coordinated the project across four institutions, with Vijayvargiya responsible for data collection, Vijayvargiya and Zhou performing the analysis and drafting, Singal contributing to conception, design, and revision, and Lipner overseeing the work and providing final approval. The authors declared no competing interests and reported no external funding for the study, and the paper was accepted on 1 September 2026 and published on 12 September 2026 in volume 318 of the journal.

The clinical importance of distinguishing herpetic whitlow from bacterial infections of the hand cannot be overstated. Misdiagnosis as a bacterial felon or paronychia has historically led to incision and drainage, a surgical intervention that is not only unnecessary for viral infection but potentially harmful, because breaching the skin can introduce secondary bacterial infection or delay appropriate antiviral therapy. Recognizing the characteristic morphology of whitlow, grouped vesicles on an erythematous base with a predilection for the distal phalanx, along with a history of prior oral or genital herpes lesions, exposure to oral secretions, or recent trauma to the digit, allows clinicians to avoid inappropriate surgery and initiate antiviral treatment promptly. Diagnostic confirmation, when needed, can be achieved through viral culture, polymerase chain reaction testing, or Tzanck smear, though the classic presentation in most cases permits clinical diagnosis.

Therapy for herpetic whitlow rests on antiviral agents, principally acyclovir, valacyclovir, and famciclovir, which shorten the duration of viral shedding and accelerate healing when initiated early in the course of infection. The pharmacogenetic pathway described by Maillard and colleagues explains both the selectivity and the limitations of these drugs: acyclovir is preferentially phosphorylated by virus-encoded thymidine kinase, concentrating active drug in infected cells, but resistance can emerge in immunocompromised patients through loss or alteration of the viral kinase, in which case drugs with alternative mechanisms, such as foscarnet, may be required. For immunocompetent patients, most episodes resolve spontaneously within two to four weeks, though recurrent disease can be frequent, painful, and disruptive, particularly for health care workers whose livelihoods depend on unimpaired hand function.

Prevention strategies highlighted across the reviewed literature emphasize simple but effective measures. The dramatic decline in occupational whitlow among dental professionals after routine gloving became standard practice stands as one of the clearest demonstrations that barrier precautions control transmission of herpes simplex virus in clinical settings. In households, parents and caregivers with active oral herpes lesions can reduce transmission to children by avoiding kissing children on or near the mouth, not sharing utensils and towels, and discouraging thumb-sucking in children with active herpetic gingivostomatitis. People with recurrent whitlow can reduce autoinoculation risk by avoiding contact between their lesions and other body sites, particularly the eyes, where herpes infection can threaten vision.

The consolidated picture that emerges from this review serves a dual purpose. For clinicians, it provides an evidence-based reference point for recognizing a condition that, despite its distinctive appearance, continues to be misdiagnosed in emergency departments, pediatric clinics, and dermatology practices. For researchers, it identifies gaps in the literature, including the relative scarcity of prospective studies and randomized treatment trials in both children and adults, since most of the evidence base remains built on individual case reports and small series. As antiviral pharmacology advances and awareness of occupational and household transmission routes deepens, syntheses of the kind now published by the Weill Cornell, Rutgers, and Columbia collaboration help ensure that the accumulated clinical wisdom of six decades of case reporting is not lost but translated into better diagnosis, more judicious treatment, and fewer preventable infections of the hand.

Subject of Research: Herpetic whitlow: a systematic review of published herpes simplex virus infection cases of the fingers

Article Title: Review of published herpetic whitlow cases

Article References: Vijayvargiya, N., Singal, A., Zhou, M. H., & Lipner, S. R. (2026). Review of published herpetic whitlow cases. Archives of Dermatological Research, 318(1), Article 412. https://doi.org/10.1007/s00403-026-04923-x

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04923-x

Keywords: herpetic whitlow, herpes simplex virus, dermatology, acyclovir, occupational infection, pediatric herpes, antiviral therapy, nail and hand infection, case report review, viral infection, dental health workers, autoinoculation

The logic of the approach rests on the tight biological relationship between cytomegalovirus and the auditory system. The virus has a pronounced affinity for the structures of the inner ear, where it can damage the cochlea and its hair cells, disrupt the stria vascularis, and inflame the auditory nerve. Damage may be present at birth or may emerge and progress over the first months and years of life, which is why congenital cytomegalovirus accounts for a substantial share of moderate to profound sensorineural hearing loss in children. Because the infection is frequently silent otherwise, a failed hearing screen is often the first and only clue that a newborn carries the virus.

Under a reflexive protocol, that clue triggers a defined sequence of actions rather than an open-ended referral. When an infant fails the initial hearing screen in one or both ears, the hospital initiates a confirmatory test for congenital cytomegalovirus, typically using a saliva or urine specimen analyzed by polymerase chain reaction. Saliva testing, in particular, has been validated as a sensitive first-line method, though care must be taken to collect the sample more than an hour after breastfeeding to avoid false positives from maternal viral shedding in breast milk. A positive saliva result is generally confirmed with urine testing, since urine offers the highest specificity for diagnosing true congenital infection.

The timing of all of this matters enormously, and it is one of the central technical reasons hearing-targeted screening has attracted both enthusiasm and scrutiny. Diagnosis of congenital cytomegalovirus is only reliable within the first three weeks of life. After that window, detection of viral DNA in saliva or urine cannot distinguish an infection acquired in the womb from one acquired during delivery or through breast milk, both of which are common and usually benign. Any screening program that depends on a failed hearing test must therefore move quickly: the hearing screen, the reflexive virologic test, and any confirmatory testing must all be completed before the infant leaves the hospital or within days of discharge if the baby is identified early enough.

Evaluating such a program at a high-volume center provides a distinctive vantage point. Large delivery services process thousands of births annually, which means the logistics of specimen collection, laboratory turnaround, result communication, and follow-up scheduling are tested at real-world scale. A protocol that works smoothly in a small pilot may strain under the throughput of a major hospital, where night and weekend births, transfers to intensive care, staffing variation, and competing nursery priorities can all disrupt the tight sequence of events a reflexive pathway requires. Conversely, high-volume centers also generate enough cases to reveal whether the strategy identifies a clinically meaningful number of infected infants rather than a handful.

The evaluation speaks to a broader, unresolved debate in newborn health policy. Universal screening, in which every newborn is tested for cytomegalovirus regardless of hearing status, maximizes case detection and is favored by many virologists and audiologists. Targeted screening, of which the reflexive hearing-triggered model is the dominant form, tests only a subset of infants and therefore misses infected babies who pass their hearing screens. This is not a trivial omission. A significant proportion of children with congenital cytomegalovirus-related hearing loss pass newborn hearing screening, because the auditory damage may be absent at birth, unilateral, mild enough to escape the screen, or delayed in onset. The virus can also cause other complications, including low birth weight, microcephaly, thrombocytopenia, and, in some cases, long-term neurodevelopmental challenges, that hearing-based selection would never flag.

Defenders of the targeted approach counter that it offers the best available compromise. Testing every infant carries costs in laboratory capacity, specimen handling, parental counseling, and the management of false positives, and the clinical pathway for a positive result remains genuinely uncertain. Antiviral treatment with valganciclovir can improve hearing and developmental outcomes in infants with symptomatic disease, and evidence supports its use in selected cases, but treatment decisions require careful weighing of efficacy against toxicity, including the risk of neutropenia and questions about long-term effects. Identifying an infant through hearing-targeted screening ensures that at least those with an early audible deficit, who are among the most likely to benefit, enter the care pathway within the diagnostic window.

A rigorous assessment of a reflexive program must therefore track several performance dimensions simultaneously. These include the proportion of infants who fail hearing screening and successfully receive virologic testing within twenty-one days, the turnaround time from failed screen to specimen collection and result, the positivity rate among tested infants, the completeness of confirmatory urine testing after an initial saliva positive, and the rate at which identified infants are linked to audiology, ophthalmology, developmental follow-up, and treatment discussions. Attrition is the perennial enemy: every additional step in a chain loses some families, whether because of missed appointments, delayed results, discharge before screening, or incomplete documentation. A high-volume evaluation is well positioned to quantify exactly where in that chain infants fall through.

The findings carry practical implications for hospitals and health systems considering adoption of similar protocols. Successful implementation at scale appears to depend on embedding the cytomegalovirus test into the existing newborn screening workflow by default, so that a failed hearing screen automatically generates a laboratory order rather than depending on individual nurses or physicians to remember and act. Standardized collection kits kept in the nursery, clear protocols for the timing of saliva collection relative to feeding, established laboratory arrangements with rapid polymerase chain reaction turnaround, and scripted counseling materials for parents all reduce the friction that otherwise erodes completion rates. The model also highlights the value of co-locating audiology and infectious disease expertise so that a positive result converts promptly into a coordinated follow-up plan rather than a series of disconnected referrals.

More broadly, the study contributes to the growing international conversation about whether congenital cytomegalovirus belongs among the conditions routinely screened at birth. Professional societies in pediatrics, audiology, and infectious disease continue to weigh the trade-offs, and several regions have moved toward universal testing while others retain targeted models. Whatever policy direction individual health systems take, the central lesson from this high-volume evaluation is that the feasibility of any congenital cytomegalovirus screening strategy rests as much on operational design as on virology. The three-week diagnostic window is unforgiving, the detection technology is mature and reliable, and the treatment evidence is evolving; what determines whether infected infants are actually found and helped is the reliability of the human and logistical machinery connecting a failed hearing test to a laboratory result and a plan of care. Careful, transparent evaluations like this one give hospitals the evidence they need to build that machinery well, and give policymakers a clearer picture of what targeted screening can, and cannot, deliver for the infants it is designed to protect.

Subject of Research: Evaluation of a reflexive, hearing-targeted newborn screening program for congenital cytomegalovirus infection at a high-volume birth center

Article Title: Evaluation of reflexive, hearing-targeted congenital cytomegalovirus screening at a high-volume center

Article References: Thompsen, K., Shah, M., Fishbein, J., Skibley, L., & Mithal, L. B. (2026). Evaluation of reflexive, hearing-targeted congenital cytomegalovirus screening at a high-volume center. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02897-2

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02897-2

Keywords: congenital cytomegalovirus, newborn screening, hearing loss, reflexive testing, sensorineural hearing loss, saliva PCR, valganciclovir, Journal of Perinatology, newborn hearing screening, diagnostic window, high-volume birth center, viral infection